GSK-partnered Alector will pull the plug on its investigational antibody latozinemab, which it had been developing for a genetic form of frontotemporal dementia, and cut 49% of its workforce. The layoffs will affect about 75 employees.
GSK-partnered Alector will pull the plug on its investigational antibody latozinemab, which it had been developing for a genetic form of frontotemporal dementia, and cut 49% of its workforce. The layoffs will affect about 75 employees.